HIV Infections Clinical Trial
Official title:
Reducing HIV & Domestic Violence Risk in Women Offenders
The long-term goal of this work is to reduce the prevalence of HIV and domestic violence
among women at risk by encouraging self-protective behaviors. To obtain this goal, Multnomah
County Health Department and Oregon Department of Human Services have conducted a randomized
trial of an intervention to prevent HIV and domestic violence among women who have recent
criminal justice involvement and who are at risk for HIV infection.
Women enrolled in the study were randomly assigned to one of three study conditions:
- Group 1: these women received information on local resources addressing HIV prevention,
domestic violence, and life stability issues; they did not receive any counseling
sessions as part of the study itself.
- Group 2: these women received up to ten supportive counseling sessions based on the
techniques of motivational interviewing. These sessions aimed to reduce HIV risk and to
improve life stability.
- Group 3: these women received up to ten supportive counseling sessions based on
motivational interviewing. These sessions aimed to reduce risk for HIV and domestic
violence and to improve life stability.
The primary hypotheses of this study were:
- 1. Supportive counseling (motivational interviewing) addressing HIV prevention and
increased life stability will lead to reductions of HIV risk behavior among women
enrolled in the study.
- 2. Supportive counseling (motivational interviewing) addressing domestic violence
prevention, HIV prevention, and increased life stability, will bring about reductions
in experiences of domestic violence and a reduction of HIV risk among these women.
- 3. The supportive counseling received in this study will enhance these women's
self-efficacy, self-esteem, and psychological well-being.
Women in all three experimental groups were interviewed at the beginning of the study and
again after 4, 7, and 10 months. These assessment interviews asked questions about: HIV
risk; experiences of domestic violence; and life stability issues such as education,
employment, and housing; and included biological testing for HIV and sexually transmitted
diseases. Women in Group 2 and Group 3 participated in up to 10 sessions of supportive
counseling (motivational interviewing) between the time of enrollment and the 4-month
interviews.
Status | Completed |
Enrollment | 530 |
Est. completion date | January 2005 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - women - who were 18 years or older - who had been in jail or prison in the past year or who were currently on parole or probation - who had engaged in HIV-related risk behaviors (injection drug use, crack use, intercourse with a male injection drug user, exchanging sex, or having had ten or more sexual partners) in the past year Exclusion Criteria: Women were excluded from the study if: - they were unable to give informed consent - they were HIV positive at the time of screening for enrollment - they reported highly unstable living conditions at screening |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | SE Health Center | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Multnomah County Health Department | Oregon Department of Human Services |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | unprotected sex | |||
Primary | injection drug use | |||
Primary | intimate partner violence | |||
Primary | violence from others | |||
Secondary | self-esteem | |||
Secondary | anxiety | |||
Secondary | depression | |||
Secondary | housing stability | |||
Secondary | employment | |||
Secondary | education |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |